Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Jaguar Health Inc

JAGX ✗ NOT COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Pharmaceuticals ·

USA Micro Cap Analyst: N/A

Last Close

$2.15

▼ -5.70%

Market Cap $4.60M · Vol 29.02K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$4.60M

Micro Cap

Div Yield

N/A

Dividend with no set frequency

EPS Growth

N/A

YoY

RSI (14)

38.91

Momentum

Beta

-0.18

vs Market

52W High

$1,118.25

99.80% below

52W Low

$2.15

0.88% above

Volume

29.02K

Avg 503.02K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

95.62%

Public shares

Shariah Compliance8 STANDARDS

✗ Jaguar Health Inc (JAGX) stock is currently not Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does JAGX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-53.16%

-93.76%

-89.46%

-99.00%

YTD

-99.56%

-99.78%

-100.00%

Financials & Valuation

TTM · Annual

Total Revenue	$11.51M
Net Income	$-53,997,000.00
Revenue Growth (YoY)	-58.88%
Gross Margin	67.21%
Operating Margin	-391.87%
Net Profit Margin	-469.09%
ROE	N/A
ROA · ROIC	-117.71% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	0.19
P/B	N/A
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	2.14M

Technical Indicators

50-Day SMA	$7.83
200-Day SMA	$134.43
RSI (14)	38.91
Beta	-0.18
52-Week High	$1,118.25
52-Week Low	$2.15

Volume Today	29.02K
Avg Daily Volume (30D)	503.02K
Relative Volume	0.06x
Volatility (10D)	171.38
Volatility (30D)	866.65
Free Float	95.62%

Analyst Consensus

N/A

Current Price $2.15

Mean Target N/A

52W Low$2.15 52W High$1,118.25

Current

Target

$2.15 $1,118.25

Current Analyst target

· 0 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG005Z205T2

ISINUS47010C8626

CountryUSA

Sub-IndustryPharmaceuticals (NEC)

Earnings DateMar 31, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Company +2.83% JNJ Johnson & Johnson +3.81% ABBV AbbVie Inc. +0.14% NVS Novartis AG +1.52% NOVN.S Novartis AG +1.58%

Company Profile

Jaguar Health, Inc. is a commercial stage pharmaceuticals company. The Company is developing prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Its marketed drug Mytesi, (crofelemer 125 mg delayed-release tablets), is a first-in-class oral botanical drug product approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Its Canalevia-CA1, crofelemer delayed-release tablets drug, is an oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea in dogs. It has an exclusive distribution agreement for the sale of Gelclair. It is developing a pipeline of prescription drug product candidates to address unmet needs in gastrointestinal health.